176 related articles for article (PubMed ID: 21177046)
1. Treatment for hepatitis C virus genotype 1 infection in HIV-infected individuals on methadone maintenance therapy.
Taylor LE; Bowman SE; Chapman S; Zaller N; Stein MD; Cioe PA; Maynard MA; McGovern BH
Drug Alcohol Depend; 2011 Jul; 116(1-3):233-7. PubMed ID: 21177046
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study.
Sulkowski MS; Fessel WJ; Lazzarin A; Berenguer J; Zakharova N; Cheinquer H; Côté P; Dieterich D; Gadano A; Matthews G; Molina JM; Moreno C; Pineda JA; Pulido F; Rivero A; Rockstroh J; Hernandez D; McPhee F; Eley T; Liu Z; Mendez P; Hughes E; Noviello S; Ackerman P
Hepatol Int; 2017 Mar; 11(2):188-198. PubMed ID: 28210927
[TBL] [Abstract][Full Text] [Related]
3. Role of pegylated interferon-alpha-2a and ribavirin concentrations in sustained viral response in HCV/HIV-coinfected patients.
Lopez-Cortes LF; Valera-Bestard B; Gutierrez-Valencia A; Ruiz-Valderas R; Jimenez L; Arizcorreta A; Terrón A; Viciana P
Clin Pharmacol Ther; 2008 Nov; 84(5):573-80. PubMed ID: 18596682
[TBL] [Abstract][Full Text] [Related]
4. Effects of pegylated interferon alfa-2b on the pharmacokinetic and pharmacodynamic properties of methadone: a prospective, nonrandomized, crossover study in patients coinfected with hepatitis C and HIV receiving methadone maintenance treatment.
Berk SI; Litwin AH; Arnsten JH; Du E; Soloway I; Gourevitch MN
Clin Ther; 2007 Jan; 29(1):131-8. PubMed ID: 17379053
[TBL] [Abstract][Full Text] [Related]
5. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.
Chung RT; Andersen J; Volberding P; Robbins GK; Liu T; Sherman KE; Peters MG; Koziel MJ; Bhan AK; Alston B; Colquhoun D; Nevin T; Harb G; van der Horst C;
N Engl J Med; 2004 Jul; 351(5):451-9. PubMed ID: 15282352
[TBL] [Abstract][Full Text] [Related]
6. Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection.
Peribañez-Gonzalez M; da Silva MH; Vilar FC; Seixas-Santos Nastri AC; Ferreira PA; Focaccia R; Mendes Correa MC
Ann Hepatol; 2013; 12(2):228-35. PubMed ID: 23396734
[TBL] [Abstract][Full Text] [Related]
7. OPERA: responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection in Italy.
Bruno R; Cariti G; Nasta P; Capetti A; Ravasio V; Galli M; Raise E; Palmieri G; Iannacone C; Puoti M
Liver Int; 2015 Jan; 35(1):120-9. PubMed ID: 25041136
[TBL] [Abstract][Full Text] [Related]
8. Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients.
Ramos B; Núñez M; Rendón A; Berdún MA; Losada E; Santos I; Echevarría S; Ocampo A; Miralles C; Arazo P; Barreiro P; Romero M; Labarga P; Guardiola JM; Garcia-Samaniego J; Soriano V
J Viral Hepat; 2007 Jun; 14(6):387-91. PubMed ID: 17501758
[TBL] [Abstract][Full Text] [Related]
9. Faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV.
Dieterich D; Nelson M; Soriano V; Arastéh K; Guardiola JM; Rockstroh JK; Bhagani S; Laguno M; Tural C; Ingiliz P; Jain MK; Stern JO; Manero M; Vinisko R; Kort J;
AIDS; 2015 Mar; 29(5):571-81. PubMed ID: 25710287
[TBL] [Abstract][Full Text] [Related]
10. Role of individualization of hepatitis C virus (HCV) therapy duration in HIV/HCV-coinfected individuals.
Hopkins S; Lambourne J; Farrell G; McCullagh L; Hennessy M; Clarke S; Mulcahy F; Bergin C
HIV Med; 2006 May; 7(4):248-54. PubMed ID: 16630037
[TBL] [Abstract][Full Text] [Related]
11. Rationale and design of a randomized controlled trial of directly observed hepatitis C treatment delivered in methadone clinics.
Litwin AH; Berg KM; Li X; Hidalgo J; Arnsten JH
BMC Infect Dis; 2011 Nov; 11():315. PubMed ID: 22078241
[TBL] [Abstract][Full Text] [Related]
12. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.
Liu CJ; Chuang WL; Lee CM; Yu ML; Lu SN; Wu SS; Liao LY; Chen CL; Kuo HT; Chao YC; Tung SY; Yang SS; Kao JH; Liu CH; Su WW; Lin CL; Jeng YM; Chen PJ; Chen DS
Gastroenterology; 2009 Feb; 136(2):496-504.e3. PubMed ID: 19084016
[TBL] [Abstract][Full Text] [Related]
13. Developing a modified directly observed therapy intervention for hepatitis C treatment in a methadone maintenance program: implications for program replication.
Bruce RD; Eiserman J; Acosta A; Gote C; Lim JK; Altice FL
Am J Drug Alcohol Abuse; 2012 May; 38(3):206-12. PubMed ID: 22242700
[TBL] [Abstract][Full Text] [Related]
14. Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study.
Dieterich D; Rockstroh JK; Orkin C; Gutiérrez F; Klein MB; Reynes J; Shukla U; Jenkins A; Lenz O; Ouwerkerk-Mahadevan S; Peeters M; De La Rosa G; Tambuyzer L; Jessner W
Clin Infect Dis; 2014 Dec; 59(11):1579-87. PubMed ID: 25192745
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients.
Dominguez S; Ghosn J; Valantin MA; Schruniger A; Simon A; Bonnard P; Caumes E; Pialoux G; Benhamou Y; Thibault V; Katlama C
AIDS; 2006 May; 20(8):1157-61. PubMed ID: 16691067
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C viral kinetics during treatment with peg IFN-alpha-2b in HIV/HCV coinfected patients as a function of baseline CD4+ T-cell counts.
Avidan NU; Goldstein D; Rozenberg L; McLaughlin M; Ferenci P; Masur H; Buti M; Fauci AS; Polis MA; Kottilil S
J Acquir Immune Defic Syndr; 2009 Dec; 52(4):452-8. PubMed ID: 19797971
[TBL] [Abstract][Full Text] [Related]
17. Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial.
Rodriguez-Torres M; Slim J; Bhatti L; Sterling R; Sulkowski M; Hassanein T; Serrão R; Sola R; Bertasso A; Passe And S; Stancic S
HIV Clin Trials; 2012; 13(3):142-52. PubMed ID: 22592094
[TBL] [Abstract][Full Text] [Related]
18. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.
Laguno M; Von Wichmann MA; Van den Eynde E; Navarro J; Cifuentes C; Murillas J; Veloso S; Martínez-Rebollar M; Guardiola JM; Jou A; Gómez-Sirvent JL; Cervantes M; Pineda JA; López-Calvo S; Carrero A; Montes ML; Deig E; Tapiz A; Ruiz-Mesa JD; Cruceta A; de Lazzari E; Mallolas J
Int J Infect Dis; 2016 Dec; 53():46-51. PubMed ID: 27815225
[TBL] [Abstract][Full Text] [Related]
19. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.
Labarga P; Barreiro P; da Silva A; Guardiola JM; Rubio R; Aguirrebengoa K; Miralles P; Portu J; Téllez MJ; Morano L; Castro A; Pineda JA; Terrón A; Hernández-Quero J; Mariño A; Ríos MJ; Echeverría S; Asensi V; Vispo E; Soriano V;
J Infect Dis; 2012 Sep; 206(6):961-8. PubMed ID: 22807523
[TBL] [Abstract][Full Text] [Related]
20. Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV-HIV-coinfected patients.
Tural C; Galeras JA; Planas R; Coll S; Sirera G; Giménez D; Salas A; Rey-Joly C; Cirera I; Márquez C; Tor J; Videla S; García-Retortillo M; Clotet B; Solà R
Antivir Ther; 2008; 13(8):1047-55. PubMed ID: 19195330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
